Editorial: Greater risk, greater benefit - True or false?

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 2, 2003, Pages 538-541

  Miller, Paul D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; EDITORIAL; FRAGILITY FRACTURE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VERTEBRA FRACTURE;

CALCIUM CHANNEL BLOCKERS; ETIDRONIC ACID; HIP FRACTURES; HUMANS; OSTEOPOROSIS; RISK FACTORS; SPINAL FRACTURES;

EID: 0037326109     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021880     Document Type: Editorial

References (32)

1. Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD, Barton I, Calligeros D, Felsenberg D 2003 Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88:542-549
2. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut III CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282:1344-1352
3. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established osteoporosis. Osteoporos Int 11:83-91
4. Black DM, Thompson D, Bauer D, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR, for the Fracture Intervention Trial 2000 Fracture reduction risk with alendronate in women with osteoporosis. J Clin Endocrinol Metab 85:4118-4124
5. Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD 2002 Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 162:1140-1143
6. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM 1993 Bone density at various sites for prediction of hip fractures. Lancet 341:72-75
7. Dargent-Molina P, Favier F, Grandjean H, Baudoin C, Schott AM, Hausherr E, Meunier PJ, Breart G, for the EPIDOS Study Group 1996 Fall-related factors and risk of hip fracture: EPIDOS prospective study. Lancet 38:145-149
8. De Laet CEDH, Van Hout BA, Burger H, Weel AE, Hofman A, Pols HA 1998 Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 13:1587-1593
9. Hui SL, Slemenda CW, Johnston Jr CC 1988 Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81:1804-1809
10. Ross PD, Davis JW, Epstein RS, Wasnich RD 1991 Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114:919-923
11. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E Risk of new vertebral fracture in the year following a fracture. JAMA 285:320-323
12. Delmas P, Genant HK, Crans G, Sirise E, Wong M, Stock J, Harper K, Adachi J 2002 Prevalent vertebral fracture severity predicts subsequent vertebral and nonvertebral fracture risk in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Osteoporos Int 13:521
13. Melton III LJ, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL 1993 Prevalence and incidence of vertebral deformities. Osteoporos Int 3:113-119
14. Greenspan SL, Von Stetten E, Emond SK, Jones L, Parker RA 2001 Instant vertebral assessment a non-invasive dual x-ray absorptiometry technique to avoid misclassification and clinical mismanagement of osteoporosis. J Clin Densitom 4:373-380
15. Schousboe JT, DeBold CR, Bowles C, Glickstein S, Rubino RK 2002 Prevalence of vertebral compression fracture deformity by x-ray absorptiometry of lateral thoracic and lumbar spines in a population referred for bone densitometry. J Clin Densitom 5:239-246
16. Siris E, Miller PD, Barrett-Conner E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM 2001 Identification and fracture outcomes of undiagnosed low bone density in postmenopausal women: results from The National Osteoporosis Risk Assessment (NORA). JAMA 286:2815-2822
17. Miller PD, Siris E, Barrett-Conner E, Faulkner KG, Wehren LE, Abbott TA, Chen YT, Berger ML, Santora AC, Sherwood LM 2002 Prediction of fracture risk on postmenopausal white women using peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res 17:2222-2230
18. Miller PD, Njeh CF, Jankowski LG, Lenchik L 2002 What are the standards by which bone mass measurements at peripheral skeletal sites should be used in the diagnosis of osteoporosis? J Clin Densitom 5(Suppl 1)S39-S46
19. Wainwright SA, Phipps KR, Stone JV, Cauley JA, Vogt MT, Black DM, Orwoll ES 2001 A large proportion of fractures in postmenopausal women occur with baseline bone mineral density T-score -2.5. J Bone Miner Res 16:S155
20. Faulkner KG, Roberts L, McClung M 1996 Discrepancies in normative database between Lunar and Hologic DXA systems. Osteoporos Int 6:432-436
21. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston Jr CC, Lindsay RL 1995 Proximal femur bone mineral levels of US adults. Osteoporos Int 5:389-409
22. Pocock NA, Sambrook PN, Kelly P, Freund J, Eisman JA 1992 Assessment of spinal and femoral bone density by dual X-ray absorptiometry: comparison of Lunar and Hologic instruments. J Bone Miner Res 9:1081-1084
23. McMahon K, Kalnins S, Freund J, et al. 2003 Discordance in lumbar spine T scores and non-standardization of standard deviations. J Clin Densitom, in press
24. Faulkner KG, Von Stetten E, Miler PD 1999 Discordance in patient classification using T scores. J Clin Densitom 2:343-350
25. Miller PD 2002 Controversial issues in bone densitometry. In: Bilezikian JP, Raisz L, Rodan G, eds. Principles of bone biology, ed 2. New York: Academic Press; 1587-1597
26. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results form the Fracture Intervention Trial. JAMA 280:2077-2082
27. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-645
28. McClung MR, Guesens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, for the Hip Intervention Program Study Group 2001 Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340
29. Writing Group for the Women's Health Initiative 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 228:321-333
30. Black D, Thompson D, Quandt S, Palmero L, Ensrud K 2002 Alendronate reduces risk of vertebral fracture in women with BMD T-scores above -2.5: results from the fracture intervention trial (FIT). J Bone Miner Res 17:S474
31. Johnell O, Kanis J, Black D, Secrest R, Sartar S, Fuerst T, Zhou C, Pavo I 2002 Raloxifene significantly reduces vertebral fracture risk in patients with osteopenia or osteoporosis defined by total hp BMD T scores. Osteoporos Int 13(Suppl 3):S69-S70
32. Kanis JA, Johnell O, Oden A, De Laet C, Oglesby A, Jonsson B 2002 Intervention thresholds for osteoporosis. Bone 31:26-31